Table I.
Baseline characteristics of participants
| Enrolled (n = 67) | |
|---|---|
| Age (y), mean ± SD | 8.6 ± 2.0 |
| Sex, male | 64% (43/67) |
| SPT | |
| Any atopy | 82.2% (53/64) |
| House dust mite | 72.6% (45/62) |
| Mold | 24.1% (14/58) |
| Pollen (ryegrass) | 30.0% (18/60) |
| Cockroach | 28.8% (17/59) |
| Cat | 23.7% (14/59) |
| Dog hair | 5.9% (2/34) |
| Alternaria species | 21.1% (12/57) |
| c-ACT score | |
| Very poorly controlled (≤12) | 1.5% (1/65) |
| Not well controlled (13-19) | 30.8% (20/65) |
| Well controlled (≥20) | 67.7% (44/65) |
| Respiratory function∗ | |
| FEV1 % predicted, mean ± SD | 99.8 ± 21.5 |
| FVC, % predicted, mean ± SD | 102.8 ± 16.5 |
| FEV1/FVC ratio, mean ± SD | 0.82 ± 0.08 |
| PEF % predicted, mean ± SD | 104.7 ± 22.3 |
| ED visits in previous 12 mo | |
| ≥1 Attendance at ED for asthma | 9.0% (6/67) |
| Medication use in previous 12 mo | |
| Any oral corticosteroids | 46.3% (31/67) |
| ICS or ICS/LABA combination | 88.1% (59/67) |
| ICS regular† | 44.8% (30/67) |
| ICS intermittent‡ | 3.0% (2/67) |
| ICS/LABA regular† | 28.4% (19/67) |
| ICS/LABA intermittent‡ | 11.9% (8/67) |
| Regular high-dose§ ICS or ICS/LABA† | 62.7% (42/67) |
| Non-ICS controller‖ (no ICS or ICS/LABA) | 3.0% (2/67) |
| SABA only | 9.0% (6/67) |
| Exposure to domestic tobacco smoke¶ | 6% (4/67) |
ED, Emergency department; SABA, short-acting β-agonist.
∗
There were 57 subjects with acceptable and reproducible spirometric records.
†
Reported to have been taken for most of the previous 12 months.
‡
Reported to have been taken intermittently or on an as-needed basis.
§
High-dose ICS: greater than 200 μg/d fluticasone propionate or equivalent.
‖
Montelukast (leukotriene receptor antagonist).
¶
Based on parental responses to “My home is smoke free” versus “People occasionally/frequently smoke in my home.”